NTR and Almac Group agree supply of additional localised clean power from Murley Wind Farm, Northern Ireland
NTR and Almac increase clean volume offtake by over 20% of the project’s production as Almac expands its operations
NTR and Almac Group agree supply of additional localised clean power from Murley Wind Farm, Northern Ireland
NTR and Almac increase clean volume offtake by over 20% of the project’s production as Almac expands its operations
Dublin, 13th February 2026:
Two years into a successful corporate PPA partnership, NTR and Commercial Drug Manufacture and Development organisation Almac Group have agreed to an increase in clean power volume to be provided from Murley wind farm located in Co. Tyrone, Northern Ireland.
Murley commenced operations in 2024, at which point NTR and Almac had agreed a PPA for just under 50% of the wind farm’s volume. With continuing success and expansion of its operations in Northern Ireland, Almac and NTR have agreed to contract additional volume from the wind farm, increasing to the equivalent of just under 70% of the windfarm’s output.
This additional renewable energy reduces carbon emissions from electricity used at Almac’s Craigavon headquarters, supporting both the company’s growth plans, and its commitment to reducing Scope 1 and 2 emissions by 50% by 2030. The Craigavon campus currently employs over 4,000 of Almac’s 7,800 global workforce.
Francisco Del Rio, Head of Power Sales Europe at NTR, said:
“This is a great example of partners growing together, whereby we are able to meet Almac’s need for additional clean power from a local source as they expand operations. Across our different markets in Europe, we are increasingly working with partners around bespoke PPAs according to their requirements, be they locational or requirements to shape power supply around their load and it’s this type of flexibility that differentiates NTR.”
Niall Harkin, Executive Director, Almac Group, said:
“We are delighted to increase our clean power volume which allows us to continue to power almost all operations at our Craigavon site as it expands, with fully certified renewable energy,” said Niall Harkin, Executive Director, Almac Group. “Almac’s participation in this project has been a crucial step on our journey to net zero and helps to significantly reduce carbon emissions from the electricity we consume.
“As a global leader in providing a range of expert services and support across the drug development lifecycle, it is crucial that we continue to demonstrate our commitment to the long-term sustainability goals of the sector. I am hugely encouraged by the progress that we are making on our climate journey.”
ENDS
Further information:
NTR Media Queries:
Gilly Lock/ Louisa Henry
NTR@sodali.com
+44 (0) 20 7100 6451
Almac Media Queries:
Eve Wallace
Angeliki Lumpkin
angeliki.lumpkin@almacgroup.com
About NTR
Established in 1978, NTR is an experienced sustainable infrastructure investor and asset manager driving Europe’s clean energy transition. Over 25 years in clean energy investment, NTR has developed, constructed and operated over 4 GW of wind, solar and energy storage projects and associated grid. NTR currently manages clean energy transition projects in circa 70 locations across seven European countries.
NTR’s mission of developing, constructing, and operating sustainable infrastructure in a responsible manner means that we incorporate an ESG mindset into every stage of the business. From initial investment assessment through to operational projects, NTR aims to have a positive impact on the environment and society while maintaining strong governance and risk management oversight.
For more information please visit: www.ntrplc.com
About Almac
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation which has grown organically, now employing 7,800 highly skilled personnel across 18 facilities including Europe, the USA and Asia.
For more information please visit: www.almacgroup.com